The Oncology HEOR Strategy team, within the MHI Value & Evidence function, leads the creation and communication of transformative evidence to shape healthcare decision-making and make a remarkable impact for patients.

Director, HEOR Strategy, CLL & Heme-Oncology (HEOR-S) – directs, develops, organizes, and implements the V&E strategy for Chronic Lymphocytic Leukemia (CLL) and disease adjacencies with concurrence of functional management to allow the development of each asset to proceed expeditiously and smoothly toward registration, PR&A and market launch in compliance with national and international governmental regulations for various asset programs, including CLL adjacencies. HSL reports to Senior Director, Heme-Oncology HEOR Strategy Team Lead and may have direct reports.

Responsibilities 

• Accountable for engagement and co-creation of holistic value evidence strategy with V&E pillars and cross-functional partners for Oncology disease areas/assets/brands, including co-creation of PCM deliverables, MHI Worldwide Scientific Plan, and Value & Evidence Plans (VEP) and ensuring timely relevance to disease area strategy, product development, competitive landscape, and the marketplace.
• Directs the design, conduct, and analysis of projects within each product area strategy across multiple programs, in partnership with V&E Centers of Excellence (PCOR, VAC, RWE, EPE, MPS) and is accountable for project execution, budget and meeting/exceeding ethical, scientific, regulatory, commercial, and quality requirements.
• HSL interacts/engages with cross-functional leaders for CLL disease area. Effectively communicates findings to internal leadership (Executive Leadership, Area VPs, GMs etc.) and external (e.g. HTAs/Payers, patient advocacy groups and KOLs etc.)
• In the post-marketing setting, this position is responsible for developing and executing V&E product life-cycle and labeling strategies. Responsible for integrating the expressed needs for value demonstration from customers (physicians, patients, payers, policy-makers), the direction of the commercial organization in product marketing and the realities of the science surrounding a product in developing strategies
• Assumes full strategic V&E support of commercialization activities including the facilitation of obtaining and maintaining market access and growing/defending the market.
• Accountable for end-to-end delivery of V&E book of work under their remit, from strategy development to content pull through.
• Accountable for ensuring strong partnership with MHI, IMAP and all relevant V&E pillars to ensure a holistic and comprehensive voice to accelerate global patient access, in cross-functional meetings
• Partners with Heme-Oncology HEOR Strategy Team Lead to shape CLL oncology patient access policy environment, including successfully engaging and collaborating HTA/ payers, clinical practice guideline organizations and US oncology pathway stakeholders
• Partners with Heme-Oncology HEOR Strategy Team Lead to establish external alliances to drive Heme-Oncology payer/pathway centric fit-for-purpose evidence generation in support of pre- and post-launch assets
• Develops and maintains CLL oncology research partnerships with academic and community oncology centers and pathways to demonstrate the clinical, economic, humanistic and societal value of innovative AbbVie therapies